The anti-nociceptive effects of a newly synthesized pentadecapeptide coded BPC 157 (an essential fragment of new organoprotective gastric juice peptide BPC) was evaluated in comparison with aspirin and morphine reference standards, in various experimental models of indirect/direct nociception and neurotoxicity: writhing (acetic acid/magnesium sulphate), tail pinching, hot-plate, and capsaicin application. BPC 157 administered either in the ng or μg per kg range, intraperitoneally, significantly reduced the reactions in the writhing (inflammatory and non-inflammatory, prostaglandin-dependent and independent) and tail pinching tests. In the hot-plate test, unlike morphine, BPC 157 had no effect on normal animals. However, when given to capsaicin treated rats, BPC 157 strongly reduced capsaicin-allodynia, either given as pretreatment or once daily for 14 days after the capsaicin injection. This reduction in capsaicin’s effect could not be obtained when BPC 157 was applied in the presence of established capsaicin-somatosensory neuron degeneration (application only on the 14th day after capsaicin), so it is possible that the effects of BPC 157 could be related specifically to the integrity of capsaicin-sensitive somatosensory neurons and their protection (e.g. primary afferent neurons having small-diameter somata and unmyelinated (C-) or thinly myelinated (A6-) fibres).
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Sikiric P, Petek M, Rucman R et al. Hypothesis: stomach stress response, diagnostic and therapeutical value: a new approach in organoprotection. Exp Clin Gastroenterol. 1991;l:15–6.
Sikirić P, Petek M, Rotkvic I et al. Antiulcerogenic and antiinflammatory effect of a new gastric juice peptide - body protection compound. Exp Clin Gastroenterol. 1991;l:17–20.
Sikirif P, Sciwerth S, Grabarevif Z et al. The significance of the gastroprotective effect of body protection compound (BPC): modulation by different procedures. Acta Physiol Hung. 1992;80:89–98.
Sikirif P, Petek M, Rucman R et al. A new gastric juice peptide, BPC - an overview of stomach/stress/organoprotection hypothesis and BPC beneficial effects. J Physiol (Paris). 1993;87 [in press].
Mppozsik G, Sikirif P, Petek M. Gastric mucosal preventing body protective compound (BPC) on the development of ethanol and HCl-induced gastric mucosal injury. Exp Clin Gastroenterol. 1991;l:87–90.
Brand L, Berman E, Schawen R et al. NE-1955. A novel, orally active anti-inflammatory analgesic. Drugs Exp Clin Res. 1987;13:259–62.
Collier HOJ, Dinnen LC, Johnson LA, Schneider C. The abdominal constriction response and its suppression by analgesic drugs in the mouse. Br J Pharmacol Chemother. 1968;32:295–310.
Gyires K, Knoll J. Inflammation and writhing syndrome inducing effect of PGE1, PGE2 and the inhibition of these actions. Pol J Pharmacol. 1975;27:257–64.
Gyires K, Torma Z. The use of the writhing in mice for screening different types of analgesics. Arch Int Pharmacodyn Ther. 1984;267:131–40.
Gyires K, Furst S, Miklya I, Badavari I, Knoll J. Analysis of the analgesic and anti-inflammatory effects of rimazolium, a pyrido-pyrimidine derivate, compared with that of prostaglandin synthesis inhibitors and morphine. Drugs Exp Clin Res. 1985;ll:493–500.
Knoll J, Gyires K, Hermecz I. l,6-Dimethyl-4-oxo-l,6,7,8,9,9a-hexahydro-4H-pyrido(l,2-a)-pyrimidine-3-caroxamide (CH-127) protects against the intestinal damage in rats caused by two weeks daily administration of indomethacin. Drugs Exp Clin Res. 1987;13:253–8.
Lampa E, Romano AR, Berino L et al. Pharmacological properties of a new non-steroidal anti-inflammatory drug: flunoxaprofen. Drugs Exp Clin Res. 1985;ll:501–9.
Rooks WH, Maloney PJ, Shott LD et al. The analgesic and anti-inflammatory profile of ketorolac and its tromethamine salt. Drugs Exp Clin Res. 1985;ll:479–92.
Sauvaire D, Michel A, Serrano JJ, Richard M. Pharmacological activity and toxicity of apyramide: comparison with non-steroidal anti-inflammatory agents. Drugs Exp Clin Res. 1987;13:247–52.
Vander Wende C, Margolin S. Analgesic test based upon experimentally induced acute abdominal pain in rats. Fed Proc. 1956;15:494.
Koster R, Anderson M, De Beer EJ. Acetic acid for analgesic screening. Fed Proc. 1959;18:412.
Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev. 1991;43:143–201.
Krieger DT. Brain peptide: what, where and why? Science. 1983;222:975–85.
Deraedt R, Jouquey S, Benzoni J, Peterfalvi M. Inhibition of prostaglandin biosynthesis by non-narcotic analgesic drugs. Arch Int Pharmacodyn. 1976;224:30–42.
Deraedt R, Jouquey S, Delevallee F, Flahaut M. Release of prostaglandins E and F in an algogenic reaction and its inhibition. Eur J Pharmacol. 1980;61:17–24.
Rainsford KD. Protective effects of the slow-release zinc complex, zinc monoglycerolate [Glyzinc(R)] on the gastrointestinal mucosae of rodents. Exp Clin Gastroenterol. 1991;l:349–60.
Rainsford KD, Whitehouse MW. Biochemical gastroprotection from acute ulceration induced by aspirin and related drugs. Biochem Pharmacol. 1980;29:1281–9.
Faden AI, Holaday JW. Opiate antagonists: a role in the treatment of hypovolemic shock. Science. 1979;205:317–8.
About this article
Cite this article
SikiriĆ, P., Gyires, K., Seiwerth, S. et al. The effect of pentadecapeptide BPC 157 on inflammatory, non-inflammatory, direct and indirect pain and capsaicin neurotoxicity. Inflammopharmacology 2, 121–127 (1993). https://doi.org/10.1007/BF02659088
- pentadecapeptide BPC 157
- essential fragment of organoprotective gastric juice peptide BPC
- writhing (acetic acid/magnesium sulphate)
- tail pinching test
- hot-plate test
- inflammatory/non-inflammatory, indirect/direct nociception
- capsaicin-sensitive somatosensory neurons integrity/protection